Home Journal Club	FAQ My Amedeo About Tranquillis Services	Flying Publisher
	Books, Journals, Podcasts, Weekly Updates, by Amedeo

Tuberculosis

Free Subscription Articles published in Antimicrob Agents Chemother Retrieve available abstracts of 53 articles: HTML format Text format

Single Articles

March 2010
1. MOLINA-TORRES CA , Ocampo-Candiani J, Rendon A, Pucci MJ, et al
   In vitro activity of a new Isothiazoloquinolone (ACH-702) against Mycobacterium tuberculosis and other mycobacteria.
   Antimicrob Agents Chemother. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
2. ANDO H , Kondo Y, Suetake T, Toyota E, et al
   Identification of katG mutations associated with high-level isoniazid resistance in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   February 2010
3. ORDWAY DJ , Shanley CA, Caraway ML, Orme EA, et al
   Evaluation of standard chemotherapy in the guinea pig model of tuberculosis.
   Antimicrob Agents Chemother. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
4. RULLAS J , Garcia JI, Beltran M, Cardona PJ, et al
   A fast standardized therapeutic efficacy assay for drug discovery in tuberculosis.
   Antimicrob Agents Chemother. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   January 2010
5. GARCIA-CONTRERAS L , Sung JC, Muttil P, Padilla D, et al
   Dry Powder PA-824 Aerosols for the Treatment of Tuberculosis in Guinea Pigs.
   Antimicrob Agents Chemother. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   
6. PASCA MR , Degiacomi G, Ribeiro AL, Zara F, et al
   Clinical Isolates of Mycobacterium tuberculosis in Four European Hospitals are Uniformly Susceptible to Benzothiazinones.
   Antimicrob Agents Chemother. 2010.
   PubMed     Text format     Related articles    Abstract available
   
   
   December 2009
7. RUSLAMI R , Nijland HM, Adhiarta IG, Kariadi SH, et al
   PHARMACOKINETICS OF ANTI TUBERCULOSIS DRUGS IN PULMONARY TUBERCULOSIS PATIENTS WITH TYPE-2 DIABETES.
   Antimicrob Agents Chemother. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   
8. HUITRIC E , Verhasselt P, Koul A, Andries K, et al
   Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor.
   Antimicrob Agents Chemother. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   October 2009
9. SAFI H , Fleischmann RD, Peterson SN, Jones MB, et al
   Allelic exchange and mutant selection demonstrate that common clinical embCAB gene mutations only modestly increase resistance to ethambutol in Mycobacterium tuberculosis.
   Antimicrob Agents Chemother. 2009.
   PubMed     Text format     Related articles    Abstract available
   
   
   September 2009
10. JUGHELI L , Bzekalava N, de Rijk P, Fissette K, et al
    High cross resistance between kanamycin, amikacin and capreomycin among Mycobacterium tuberculosis isolates from Georgia and a close relation with mutations in the rrs gene.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
11. DAVIS SL , Nuermberger EL, Um P, Vidal C, et al
    Non-invasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
12. YOUNG LS
    Reconsidering Some Approved Antimicrobial Agents for Tuberculosis.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2009
13. DUONG AD , Hong Duyen NT, Lan NT, Hoa DV, et al
    Beijing genotype of Mycobacterium tuberculosis is significantly associated with high-level fluoroquinolone resistance in Vietnam.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
14. VON GROLL A , Martin A, Jureen P, Hoffner S, et al
    Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
15. PARK SH , Yang SK, Yang DH, Kim KJ, et al
    Six-month versus 9-month therapy for intestinal tuberculosis: A prospective randomized trial.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
16. MANOSUTHI W , Sungkanuparph S, Tantanathip P, Mankatitham W, et al
    Body Weight Cutoff for Daily Dosage of Efavirenz and 60-week Efficacy of Efavirenz-based Regimen in Co-infected HIV and Tuberculosis Patients Receiving Rifampin.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2009
17. ALMEIDA D , Nuermberger E, Tasneen R, Rosenthal I, et al
    Paradoxical effect of isoniazid on the activity of the rifampin-pyrazinamide combination in the mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
18. BANAEI N , Kincaid EZ, Lin SY, Desmond E, et al
    Lipoprotein processing is essential for resistance of Mycobacterium tuberculosis to malachite green.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
19. GOUDE R , Amin AG, Chatterjee D, Parish T, et al
    The EmbC arabinosyltransferase is inhibited by ethambutol in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
20. HO YM , Sun YJ, Wong SY, Lee AS, et al
    Contribution of dfrA and inhA Mutations to the Detection of Isoniazid-Resistant Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2009
21. RAMON-GARCIA S , Martin C, Thompson CJ, Ainsa JA, et al
    The role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses and growth.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
22. MCGEE B , Dietze R, Hadad DJ, Molino LP, et al
    Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
23. FORGACS P , Wengenack NL, Hall L, Zimmerman SK, et al
    Tuberculosis and Trimethoprim-Sulfamethoxazole.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2009
24. FEUERRIEGEL S , Cox HS, Zarkua N, Karimovich HA, et al
    Sequence analyses of just four genes to detect extensively drug resistant tuberculosis among MDR-TB patients undergoing treatment.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
25. GUMBO T , Siyambalapitiyage Dona CS, Meek C, Leff R, et al
    Pharmacokinetics-Pharmacodynamics of Pyrazinamide In A Novel In Vitro Model of Tuberculosis for Sterilizing Effect: A Paradigm for Faster Assessment of New Antituberculosis Drugs.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
26. NIKONENKO BV , Reddy VM, Protopopova M, Bogatcheva E, et al
    Activity of SQ641, a Capuramycin Analog, in Murine Model of Tuberculosis (TB).
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2009
27. XU P , Li X, Zhao M, Gui X, et al
    Prevalence of Fluoroquinolone Resistance among Tuberculosis Patients in Shanghai, China.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2009
28. MATHYS V , Wintjens R, Lefevre P, Bertout J, et al
    Molecular genetics of para-aminosalicylic acid (PAS) resistance in clinical isolates and spontaneous mutants of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    January 2009
29. RAMACHANDRAN G , Hemanth Kumar AK, Rajasekaran S, Kumar P, et al
    CYP2B6 G516T polymorphism but not rifampicin co-administration influence steady state pharmacokinetics of efavirenz in HIV-infected patients in south India.
    Antimicrob Agents Chemother. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    December 2008
30. STARKS AM , Gumusboga A, Plikaytis BB, Shinnick TM, et al
    Mutations at embB306 are an important molecular indicator of ethambutol resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
31. WILLIAMS KN , Stover CK, Zhu T, Tasneen R, et al
    Promising anti-tuberculosis activity of the oxazolidinone PNU-100480 relative to linezolid in the murine model.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
32. VAN DEN BOOGAARD J , Kibiki GS, Kisanga ER, Boeree MJ, et al
    NEW DRUGS AGAINST TUBERCULOSIS: Problems, progress and evaluation of agents in clinical development.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    November 2008
33. DOOLEY K , Flexner C, Hackman J, Peloquin CA, et al
    Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations.
    Antimicrob Agents Chemother. 2008;52:4037-42.
    PubMed     Text format     Related articles    Abstract available
    
    
    October 2008
34. WOOLHISER LK , Hoff DR, Marietta KS, Orme IM, et al
    Testing of experimental compounds in a relapse model of tuberculosis using GM-CSF gene-disrupted mice.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    August 2008
35. IWAMOTO T , Yoshida S, Suzuki K, Wada T, et al
    Population structure analysis of the Mycobacterium tuberculosis Beijing family indicates an association between certain sublineages and multidrug resistance.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
36. HOFF DR , Caraway ML, Brooks EJ, Driver ER, et al
    Metronidazole lacks antibacterial activity in Guinea pigs infected with M. tuberculosis.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
37. TASNEEN R , Tyagi S, Williams K, Grosset J, et al
    Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in the murine model of tuberculosis.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    July 2008
38. LOUNIS N , Gevers T, Van Den Berg J, Andries K, et al
    Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model.
    Antimicrob Agents Chemother. 2008.
    PubMed     Text format     Related articles    Abstract available
    
    
    
39. VICENTE E , Villar R, Burguete A, Solano B, et al
    The Efficacy of Quinoxaline-2-carboxylate 1,4-di-N-oxide Derivatives in Experimental Tuberculosis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2008
40. HAZBON MH , Motiwala AS, Cavatore M, Brimacombe M, et al
    Convergent evolutionary analysis identifies significant mutations in drug resistance targets of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
41. MOKROUSOV I , Otten T, Manicheva O, Potapova Y, et al
    Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
42. SPIES FS , Almeida da Silva PE, Ribeiro MO, Rossetti ML, et al
    Identification of mutations related to streptomycin resistance in clinical isolates of Mycobacterium tuberculosis and possible involvement of efflux mechanism.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    May 2008
43. RUSTOMJEE R , Diacon AH, Allen J, Venter A, et al
    Early bactericidal activity and pharmacokinetics of the Diarylquinoline TMC 207 in pulmonary tuberculosis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
44. DANILCHANKA O , Mailaender C, Niederweis M
    Identification of a novel multidrug efflux pump of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    April 2008
45. MATRAT S , Aubry A, Mayer C, Jarlier V, et al
    Mutagenesis in the {alpha}3{alpha}4 GyrA Helix and in the Toprim domain of GyrB Refines the Contribution of Mycobacterium tuberculosis DNA Gyrase to Intrinsic Resistance to Quinolones.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
46. HUANG TS , Liu YC, Sy CL, Chen YS, et al
    In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis complex Isolated in Taiwan over Ten Years.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
47. WILKINS JJ , Savic RM, Karlsson MO, Langdon G, et al
    Population pharmacokinetics of rifampin in pulmonary tuberculosis patients including a semi-mechanistic model to describe variable absorption.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    March 2008
48. SAFI H , Sayers B, Hazbon MH, Alland D, et al
    Transfer of embB306 mutations into clinical Mycobacterium tuberculosis alters susceptibility to ethambutol, isoniazid and rifampin.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
49. ALFFENAAR JW , de Vries PM, Luijckx GJ, van Soolingen D, et al
    Plasma and CSF pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
50. JUREEN P , Werngren J, Toro JC, Hoffner S, et al
    Pyrazinamide Resistance and pncA Gene Mutations in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    February 2008
51. NUERMBERGER E , Tyagi S, Tasneen R, Williams KN, et al
    Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin and pyrazinamide in the murine model of tuberculosis.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    
52. LENAERTS AJ , Bitting C, Woolhiser L, Gruppo V, et al
    Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
    Antimicrob Agents Chemother. 2008;.
    PubMed     Text format     Related articles    Abstract available
    
    
    June 2007
53. ACOSTA EP , Kendall MA, Gerber JG, Alston-Smith B, et al
    Effect of Concomitant Rifampin on the Pharmacokinetics and Safety of Twice-Daily Atazanavir: ACTG Protocol A5213.
    Antimicrob Agents Chemother. 2007;.
    PubMed     Text format     Related articles    Abstract available   Free Full Text
    
    

Thank you for your interest in scientific medicine.

This AMEDEO Service was made possible thanks to the generous unrestricted educational grants provided by Pfizer.

Amedeo is a Flying Publisher website.    Design: